PREPARATION AND CHARACTERIZATION OF TOLTERODINE TARTRATE PRONIOSOMES
Adim Ekene Ugochukwu1, Obeta Judith Nnedimkpa2, Ngwu Ogochukwu Rita3
1Department of Biochemistry, Ahmadu Bello University Zaria, Nigeria.
2University of Nigeria Nsukka, Nigeria, 3Caritas University Enugu, Nigeria.

ABSTRACT
Objective: Proniosomes are dry free flowing, granular products that are water soluble carrier particles, coated with surfactants and can be hydrated to form niosomal dispersion immediately before use in hot aqueous media. Tolterodine, is medication used to treat frequent urination, urinary incontinence, or urinary urgency. It acts on M2 and M3 subtypes of muscarinic receptors.
Methods: Tolterodine tartrate proniosome formulations were prepared by coacervation phase separation method by using different surfactants in different ratios. The prepared proniosomal formulations were evaluated for vesicle size, rate of spontaneity, encapsulation efficiency, drug content, In vitro release study and stability studies.
Results: The size range was found to be 15.28±0.33 to 16.43±0.22 µm. Viscosity of all formulations lies in the range of 7244-9314 cp. Maximum release was shown by formulations of batch PG4 (87.45 %), and minimum for formulations of batch PG4 (50%), after 12 h. Optimized formulations PG4 shows stability at different temperatures.
Conclusion: Tolterodine tartrate proniosome formulations prepared by using coacervation phase separation method are capable of releasing drug for the extended period of time.
Keywords: In vitro release, proniosomes, Tolterodine tartrate.

INTRODUCTION
At present scenario vesicular systems have been receiving a lot of interest as a carrier for advanced drug delivery1. Encapsulation of the drug in vesicular structures is one such system, which can be expected to prolong the duration of the drug in systemic circulation2. Proniosomes are water soluble carrier particles that are coated with surfactants and can be hydrated to form niosomal dispersion immediately before use in hot aqueous media. Proniosome is a dry free flowing, granular product that could be hydrated immediately before use and would avoid many of the problems associated with aqueous niosome dispersions and problem of physical stability3. Proniosome technology offers novel solution for poorly soluble drugs. Proniosomes avoid many of the problems associated with aqueous niosome dispersions, and problems of physical stability (aggregation, fusion, leaking) could be minimized. The additional convenience of the transportation, distribution, storage, and dosing would make ‘dry niosomes’ a promising industrial product4.

Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. Tolterodine tartrate is used for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency5. Use of Tolterodine tartrate is associated with side effects like dry mouth and other side effects like constipation, headache, stomach pain and blurred vision, often leading to discontinuation of therapy6. The aim of present study includes development of proniosomes of Tolterodine tartrate to reduce dosing frequency and avoid side effects.

MATERIALS AND METHODS
Tolterodine tartrate was obtained as gift sample from Churchbells Pharma Nigeria Limited. Span 60, Tween 40 and cholesterol were procured from Drugfield Pharmaceuticals Limited, Nigeria. Ethyl alcohol and lecithin was procured from Interpharma Industries Nigeria Limited. All other reagents used were of analytical grades.
Preparation of proniosomal gel
Tolterodine tartrate proniosomal gel formulations were prepared by coacervation phase separation method. Precisely weighed amounts of surfactant, lipid phase and drug were taken in a clean and dry wide mouthed glass vial of 5.0 ml capacity and alcohol was added to it. All the ingredients were mixed well with a glass rod; the open end of the glass vial was covered with a lid to prevent the loss of solvent from it and warmed over water bath at 50-60°C for about 5 minutes until the drug is dissolved completely in surfactant mixture. Then the aqueous phase 1.6ml phosphate buffer (pH 7.4) was added and warmed on a water bath until a clear solution was formed. Preliminary the composition of these formulations is reported in Table 1 and they are referred as PG1 to PG4.

Evaluation of proniosome formulations
Vesicle size analysis
Hydration of Tolterodine tartrate proniosomal gel (100 mg) was done by adding saline solution (0.9% solution) in a small glass vial with occasional shaking for 10 min. The dispersion was observed under optical microscope at 45x magnification. The sizes of 200-300 vesicles were measured using a calibrated ocular and stage micrometer (Erma, Tokyo) fitted in the optical microscope.

Drug content
In a 100 ml volumetric flask, 20 mg of proniosomal gel formulations were taken, and volume was made up to mark with pH 7.4. The flask was shaken for 12 hours using an orbital shaker incubator (Finlab, Nigeria). Then the solution was filtered and from the filtrate containing vesicles were measured using an ultraviolet spectrophotometer (λ max 261 nm) and appropriate dilutions were made and absorbance was measured at 261 nm.

Encapsulation efficiency
To evaluate the loading capacity of proniosomal formulations of Tolterodine tartrate gel (100 mg) was done by adding saline solution (0.9% solution) in a small glass vial with occasional shaking for 10 min. The dispersion was observed under optical microscope at 45x magnification. The sizes of 200-300 vesicles were measured using a calibrated ocular and stage micrometer (Erma, Tokyo) fitted in the optical microscope.

RESULTS AND DISCUSSION
Results of vesicle size of Tolterodine tartrate proniosome formulations are presented in Table 2, which indicated that vesicle formed with Span 60 is smaller in size than vesicle formed with Tween 40. The reason for this may be higher hydrophobicity of Span 60 as compared to Tween 8. As hydrophobicity increases, surface energy of surfactants decreases, resulting in smaller vesicle size. The size range was found to be 15.28±0.33 to 16.43±0.22 µm. Viscosity of all formulations lies in the range of 7244-9314 cp. Drug content is important parameter to maintain the

Table 1: Composition of Tolterodine tartrate pronisomal gel formulations.

<table>
<thead>
<tr>
<th>Code</th>
<th>Drug (mg)</th>
<th>Span 60 (mg)</th>
<th>Tween 40 (mg)</th>
<th>Ethyl alcohol (ml)</th>
<th>Lecithin (mg)</th>
<th>Cholesterol (mg)</th>
<th>Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>PG1</td>
<td>100</td>
<td>1500</td>
<td>10</td>
<td>900</td>
<td>200</td>
<td></td>
<td>Yellowish gel</td>
</tr>
<tr>
<td>PG2</td>
<td>100</td>
<td>1500</td>
<td>-</td>
<td>1800</td>
<td>400</td>
<td></td>
<td>Creamish semisolid</td>
</tr>
<tr>
<td>PG3</td>
<td>100</td>
<td>1500</td>
<td>-</td>
<td>900</td>
<td>200</td>
<td></td>
<td>White semisolid</td>
</tr>
<tr>
<td>PG4</td>
<td>100</td>
<td>-</td>
<td>1500</td>
<td>1800</td>
<td>400</td>
<td></td>
<td>Yellowish gel</td>
</tr>
</tbody>
</table>

Table 2: Characterization of the proniosomal formulations of Tolterodine tartrate.

<table>
<thead>
<tr>
<th>Batch Code</th>
<th>Mean particle size (µm)</th>
<th>Encapsulation efficiency (%)</th>
<th>% Drug content</th>
<th>pH</th>
<th>Viscosity (cp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PG1</td>
<td>15.28±0.33</td>
<td>77.2±0.45</td>
<td>95±0.32</td>
<td>7.12</td>
<td>7244</td>
</tr>
<tr>
<td>PG2</td>
<td>8.34±0.45</td>
<td>79.4±0.39</td>
<td>88±0.12</td>
<td>7.34</td>
<td>8247</td>
</tr>
<tr>
<td>PG3</td>
<td>7.27±0.67</td>
<td>81.2±0.48</td>
<td>90±0.77</td>
<td>7.42</td>
<td>9314</td>
</tr>
<tr>
<td>PG4</td>
<td>16.43±0.22</td>
<td>88.3±0.55</td>
<td>99±0.47</td>
<td>7.11</td>
<td>7642</td>
</tr>
</tbody>
</table>
minimum effective concentration and it is also used to estimate the drug release profile. The percent drug content was higher for PG4 that is 99±0.47% and lower for PG2 (88±0.12%).

**Figure 1:** Comparative in-vitro release study of different proniosome formulations of Tolterodine tartrate

*In vitro* release studies (Figure 1) are often performed to predict how a delivery system might work in an ideal situation. The amount of drug released from different proniosomal formulations was found in the order of PG4 > PG3 > PG2> PG1. *In vitro* release study were performed on different proniosomal gel formulations shows maximum release for formulations of batch PG4 (87.45 %), and minimum for formulations of batch PG4 (50%), after 12 h.

**Figure 2:** Stability study of formulation (PG4) at different temperature conditions

Stability studies performed on optimized formulations PG4 shows 96.74% drug content at refrigeration condition, 94.74% drug content at oven condition and 99.59% drug content at room temperature during the studies performed for 12 weeks on the formulations (Figure 2). Thus the room temperature is the favorable storage condition for storage of proniosomes.

**CONCLUSION**

The results of investigation demonstrated that proniosomes offers an alternative colloidal carrier approach. The results obtained from the present study clearly revealed that Tolterodine tartrate proniosome formulations prepared by using coacervation phase separation method are capable of releasing drug for the extended period of time. Results of the present work have shown that surfactant type affect the encapsulation efficiency and drug release rate from proniosomes. Based on different parameters formulation of batch PG4 was considered as an optimum formulation.

**AUTHOR’S CONTRIBUTION**

The manuscript was carried out, written, and approved in collaboration with all authors.

**CONFLICT OF INTEREST**

The authors have declared that there is no conflict of interest related to this work.

**REFERENCES**


